Fulvestrant clinical trials
Also written Faslodex, ZD9238 and ICI 182,780.
ClinicalTrials.gov finds 615 studies for Fulvestrant. How that becomes 122 here
Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives Fulvestrant. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 615Found by its intervention search · See all 615 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 517 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −7
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerNCT01231659 · Earlier treatment, not given in this studyReport a problem
- Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy IndexNCT01701050 · Not named in the record; endocrine therapy unspecifiedReport a problem
- A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerNCT01823835 · Earlier treatment, not given in this studyReport a problem
- Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersNCT02734615 · Not given; a new SERD with ribociclib or alpelisibReport a problem
- Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)NCT04227327 · Earlier treatment, not given in this studyReport a problem
- Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast CancerNCT05079360 · Earlier treatment, not given in this studyReport a problem
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaNCT06843967 · Not given; named only in palbociclib's indicationsReport a problem
- 608Give Fulvestrant to participants
- −53Observe patients on it, or give it outside a trial
- −2Use it as a tool: an imaging tracer or a test of drug response
- −29Compare another treatment with it
- −402Give it beside what is tested
- 122Test it: the count on this site
Get an email when these change. Save the Fulvestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Apr 2002 · FASLODEX · NDA 021344 (FDA, Drugs@FDA)
- European Union
- 9 Mar 2004 · Faslodex · EMEA/H/C/000540 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
122 studies that test it; most in 2004 (14)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 14 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 9 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 93
AstraZeneca (21) · M.D. Anderson Cancer Center (3) · UNICANCER (3) · Alliance for Clinical Trials in Oncology (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Spanish Breast Cancer Research Group (3) · Fudan University (3) · Memorial Sloan Kettering Cancer Center (2)
Often tested with
Tested in the same studies.
Anastrozole (13) · Palbociclib (7) · Abemaciclib (7) · Tamoxifen (5) · Neratinib (4) · Alpelisib (3) · Olaparib (3) · Ribociclib (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 11 phase 3 studies under way
Fulvestrant is the comparator. A study of two new drugs counts under both.
- 2Giredestrant · Genentech, Inc., Hoffmann-La Roche · next primary completion Apr 2028
- 2Letrozole · AstraZeneca, Celcuity Inc · next primary completion Mar 2029
- 2HRS-8080 · Shandong Suncadia Medicine Co., Ltd. · next primary completion Aug 2027
- 1Palazestrant · Olema Pharmaceuticals, Inc.
- 1SIM0270 · Jiangsu Simcere Pharmaceutical Co., Ltd. · next primary completion Aug 2028
- 1Imlunestrant · Eli Lilly and Company
- 1Vepdegestrant · Pfizer
- 1AZD5305 · AstraZeneca · next primary completion Dec 2029
New treatments tested with it · 8 most studied
New when their studies opened, with Fulvestrant beside them; studies of each.
Reaching primary completion within a year · 10, 1 in phase 3
Studies that test Fulvestrant, phase 3 first.
- Apr 2027Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryPhase 3 · Alliance for Clinical Trials in Oncology
- Nov 2026Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsPhase 1 · University of Chicago
- Dec 2026A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsPhase 1 · Hunan Cancer Hospital
- Dec 2026Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerPhase 2 · The Methodist Hospital Research Institute
- Mar 2027Efficacy and Safety of 500mg of FulvestrantPhase 2 · Beth Israel Deaconess Medical Center
- Apr 2027Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerPhase 1/2 · Jonsson Comprehensive Cancer Center
- Sep 2027A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerPhase 2 · Royal Marsden NHS Foundation Trust
- Sep 2027Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaPhase 2 · M.D. Anderson Cancer Center
- Nov 2027A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerPhase 2 · Xijing Hospital
Studies
Open first, then newest update. How each study uses Fulvestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 122
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruitingPhase 2Beijing Konruns Pharmaceutical Co., Ltd.NCT07937605Written as FulvestrantReport a problem
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Written as FulvestrantReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With anastrozole and abemaciclibWritten as FulvestrantReport a problem
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390With inavolisib and ribociclibWritten as Inavolisib + Ribociclib + FulvestrantReport a problem
- Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female VolunteersRecruitingPhase 1Kashiv BioSciences, LLCNCT06995482A new fulvestrant product against Faslodex in healthy womenWritten as FulvestrantReport a problem
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT05305924A run-in alone before abemaciclib is addedReport a problem
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07333937With neratinib and eribulin in HR+/HER2+ diseaseWritten as Neratinib Combined with Fulvestrant and EribulinReport a problem
- Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingPhase 1University of ChicagoNCT06663072With Lu-DOTATATE in pancreatic neuroendocrine tumoursWritten as FulvestrantReport a problem
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingPhase 2Yeon Hee ParkNCT06849947With ribociclib after adjuvant CDK4/6, against physician's choiceWritten as Ribociclib with fulvestrantReport a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingPhase 1Hunan Cancer HospitalNCT07163481With sacituzumab govitecanWritten as Sacituzumab Govitecan + FulvestrantReport a problem
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 2Sarah K. Lynam MDNCT05113368With regorafenib in low-grade serous ovarian cancerWritten as FulvestrantReport a problem
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingPhase 4Prof. Wolfgang JanniNCT05362760One endocrine option with abemaciclib, a phase 4 studyWritten as Abemaciclib + FulvestrantReport a problem
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingPhase 2Seoul National University HospitalNCT05536128With olaparib after a CDK4/6 inhibitorWritten as FulvestrantReport a problem
- Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerRecruitingPhase 2Korea University Guro HospitalNCT05816655Added to an aromatase inhibitor and ribociclibWritten as Fulvestrant plus AI plus ribociclibReport a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266With palbociclib on ctDNA relapse against standard therapyWritten as Fulvestrant injectionReport a problem
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerRecruitingPhase 3Herui YaoNCT04263298Against capecitabine as maintenanceWritten as FulvestrantReport a problem
- Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04646759Against capecitabine, both with pyrotinibWritten as Fulvestrant combined with PyrotinibReport a problem
- Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04337658Against capecitabine, with HER2 drugs in both armsWritten as FulvestrantReport a problem
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingPhase 2Criterium, Inc.NCT04567420With palbociclib on ctDNA, against standard adjuvant therapyWritten as FulvestrantReport a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786With alpelisib and trastuzumab against chemotherapy (ALPHABET)Written as FulvestrantReport a problem
See all 122 studies that test Fulvestrant →
Behind its US label · 5 — the studies the FDA label of FASLODEX, FULVESTRANT, CLIGAVYX describes
From the Clinical Studies section of FASLODEX (2020-09), FULVESTRANT (2026-03), CLIGAVYX (2026-06), as openFDA has it. A study the site does not hold is left out.
- Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingPhase 3AstraZenecaNCT00099437Report a problem
- Second Line Breast Cancer TrialCompletedPhase 3AstraZenecaNCT00635713Report a problem
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedPhase 3AstraZenecaNCT01602380Report a problem
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02107703Report a problem
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedPhase 3Novartis PharmaceuticalsNCT02422615Report a problem
Tested on its own · 38 — no other medicine in its arm
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerRecruitingPhase 3Herui YaoNCT04263298Against capecitabine as maintenanceWritten as FulvestrantReport a problem
- Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingPhase 3AstraZenecaNCT00099437On the US label500 mg against 250 mg (CONFIRM)Written as FulvestrantReport a problem
- Efficacy and Safety of 500mg of FulvestrantActive, not recruitingPhase 2Beth Israel Deaconess Medical CenterNCT00585507The 500 mg doseWritten as FulvestrantReport a problem
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedPhase 3AstraZenecaNCT01602380On the US labelAgainst anastrozole first-line (FALCON)Written as faslodex 500mgReport a problem
- FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia StudyCompletedPhase 2Frederic AmantNCT03926936In hormone-sensitive gynaecological cancers (FUCHSia)Written as FulvestrantReport a problem
- Molecular Imaging of Fulvestrant Effects on Availability of ER Binding SitesCompletedPhase 2University Medical Center GroningenNCT01377324Its effect on oestrogen receptor imagingReport a problem
- A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantTerminatedPhase 2Atossa Therapeutics, Inc.NCT02540330Intraductal against intramuscular before surgeryWritten as FulvestrantReport a problem
- Faslodex in McCune-Albright SyndromeCompletedPhase 2AstraZenecaNCT00278915In McCune-Albright syndromeWritten as FulvestrantReport a problem
- Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic StudyCompletedPhase 1Kashiv BioSciences, LLCNCT06074757A new injection, single and multiple dosesWritten as Fulvestrant injectionReport a problem
- A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedPhase 4AstraZenecaNCT02447328Safety in later lines, a phase 4 studyWritten as FulvestrantReport a problem
- Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM AdministrationCompletedPhase 1Eagle Pharmaceuticals, Inc.NCT03324061A new suspension against FaslodexWritten as Fulvestrant for Injectable SuspensionReport a problem
- Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.TerminatedPhase 1Icahn School of Medicine at Mount SinaiNCT02936206Against tamoxifen, effect on breast cancer cellsWritten as FulvestrantReport a problem
- Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerCompletedPhase 2Institut BergoniéNCT00871858Against anastrozoleWritten as fulvestrantReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedPhase 2AstraZenecaNCT00313170Dose schedules comparedWritten as FulvestrantReport a problem
- Estrogen Receptor Antagonist in Patients With Pulmonary Arterial HypertensionCompletedPhase 2University of PennsylvaniaNCT02911844In pulmonary arterial hypertensionWritten as FulvestrantReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedPhase 2AstraZenecaNCT00274469Against anastrozole first-line (FIRST)Written as fulvestrantReport a problem
- Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial CancerStatus unknownPhase 2Gynecologic Oncology GroupNCT00006903Alone in recurrent endometrial cancerWritten as FulvestrantReport a problem
- Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerStatus unknownPhase 2Sun Yat-sen UniversityNCT02000193As maintenance after first-line chemotherapyWritten as fulvestrantReport a problem
- Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial CancerCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT00617188Alone in recurrent ovarian cancerWritten as FulvestrantReport a problem
- The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerStatus unknownPhase 2Fudan UniversityNCT03202862In ESR1-mutated metastatic breast cancerWritten as FulvestrantReport a problem
Showing 20 of 38. See all 38 →
Tested with established drugs · 18 — they are given beside it
- Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingPhase 1University of ChicagoNCT06663072With Lu-DOTATATE in pancreatic neuroendocrine tumoursWritten as FulvestrantReport a problem
- Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerRecruitingPhase 2Korea University Guro HospitalNCT05816655Added to an aromatase inhibitor and ribociclibWritten as Fulvestrant plus AI plus ribociclibReport a problem
- Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04337658Against capecitabine, with HER2 drugs in both armsWritten as FulvestrantReport a problem
- PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompletedPhase 3UNICANCERNCT03079011Switched to on rising ESR1 ctDNA (PADA-1)Written as Fulvestrant Injectable ProductReport a problem
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyTerminatedPhase 2M.D. Anderson Cancer CenterNCT04256941Added for ESR1 mutations to an aromatase inhibitor and CDK4/6Written as FulvestrantReport a problem
- Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerCompletedPhase 2MedSIRNCT02491983Against letrozole with palbociclib (PARSIFAL)Written as FulvestrantReport a problem
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs AnastrozoleTerminatedPhase 3Spanish Breast Cancer Research GroupNCT00543127Added to anastrozoleWritten as FulvestrantReport a problem
- S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast CancerCompletedPhase 3SWOG Cancer Research NetworkNCT00075764Added to anastrozole first-line (S0226)Written as fulvestrantReport a problem
- Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast CancerCompletedPhase 2Mothaffar RimawiNCT00570323Added to anastrozoleWritten as FaslodexReport a problem
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedPhase 2Translational Oncology Research InternationalNCT00100854Added to erlotinib in lung cancerWritten as fulvestrantReport a problem
- A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast CancerCompletedPhase 2Fudan UniversityNCT02137083Added to docetaxelWritten as FulvestrantReport a problem
- Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABCWithdrawnPhase 2Fudan UniversityNCT02140437Added to anastrozole in luminal A-like diseaseWritten as FulvestrantReport a problem
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast CancerStatus unknownPhase 2Hospital Affiliated to Military Medical Science, BeijingNCT02072512With goserelin against anastrozole with goserelinWritten as FulvestrantReport a problem
- Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedPhase 3AstraZenecaNCT00256698Added to anastrozole (FACT)Written as FulvestrantReport a problem
- Faslodex Advanced Breast Cancer Local Chinese StudyCompletedPhase 3AstraZenecaNCT00327769Added to anastrozole in Chinese womenWritten as FulvestrantReport a problem
- Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedPhase 2AstraZenecaNCT00357110Added to adjuvant anastrozoleWritten as FulvestrantReport a problem
- Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular StudiesCompletedPhase 2The Center for Rheumatic Disease, Allergy, & ImmunologyNCT00417430In systemic lupus erythematosusWritten as ICI 182,780 (Faslodex)Report a problem
- Second Line Breast Cancer TrialCompletedPhase 3AstraZenecaNCT00635713On the US labelDoses with anastrozole, before approvalWritten as FulvestrantReport a problem
Tested in a combination · 66 — another drug in the study is under test too
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruitingPhase 2Beijing Konruns Pharmaceutical Co., Ltd.NCT07937605Written as FulvestrantReport a problem
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Written as FulvestrantReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With anastrozole and abemaciclibWritten as FulvestrantReport a problem
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390With inavolisib and ribociclibWritten as Inavolisib + Ribociclib + FulvestrantReport a problem
- Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female VolunteersRecruitingPhase 1Kashiv BioSciences, LLCNCT06995482A new fulvestrant product against Faslodex in healthy womenWritten as FulvestrantReport a problem
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT05305924A run-in alone before abemaciclib is addedReport a problem
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07333937With neratinib and eribulin in HR+/HER2+ diseaseWritten as Neratinib Combined with Fulvestrant and EribulinReport a problem
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingPhase 2Yeon Hee ParkNCT06849947With ribociclib after adjuvant CDK4/6, against physician's choiceWritten as Ribociclib with fulvestrantReport a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingPhase 1Hunan Cancer HospitalNCT07163481With sacituzumab govitecanWritten as Sacituzumab Govitecan + FulvestrantReport a problem
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 2Sarah K. Lynam MDNCT05113368With regorafenib in low-grade serous ovarian cancerWritten as FulvestrantReport a problem
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingPhase 4Prof. Wolfgang JanniNCT05362760One endocrine option with abemaciclib, a phase 4 studyWritten as Abemaciclib + FulvestrantReport a problem
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingPhase 2Seoul National University HospitalNCT05536128With olaparib after a CDK4/6 inhibitorWritten as FulvestrantReport a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266With palbociclib on ctDNA relapse against standard therapyWritten as Fulvestrant injectionReport a problem
- Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04646759Against capecitabine, both with pyrotinibWritten as Fulvestrant combined with PyrotinibReport a problem
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingPhase 2Criterium, Inc.NCT04567420With palbociclib on ctDNA, against standard adjuvant therapyWritten as FulvestrantReport a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786With alpelisib and trastuzumab against chemotherapy (ALPHABET)Written as FulvestrantReport a problem
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06110793With lenvatinib and pembrolizumabWritten as FulvestrantReport a problem
- Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03643510With abemaciclib in recurrent endometrial cancerWritten as FulvestrantReport a problem
- Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03531645With abemaciclib in low-grade serous ovarian cancerWritten as FulvestrantReport a problem
- Endocrine Response in Women With Invasive Lobular Breast CancerCompletedPhase 2Priscilla McAuliffeNCT02206984Against tamoxifen and anastrozole before surgery in lobular cancerWritten as FulvestrantReport a problem
Showing 20 of 66. See all 66 →
Beside an established treatment under test · 54 — an approved drug, surgery or radiation is what the study tests
Tested with Fulvestrant: palbociclib 10 · Alpelisib 9 · Surgery or a procedure 3 · capivasertib 3 · Everolimus 3 · Sirolimus 3 · inavolisib 3 · abemaciclib 2
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208In every armPartner of inavolisib, with or without palbociclibWritten as FulvestrantReport a problem
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07368998In every armPartner of inavolisib after its approvalWritten as FulvestrantReport a problem
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801In every armBoth arms take it with ribociclib; inavolisib is addedWritten as FulvestrantReport a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754One endocrine maintenance option after T-DXdReport a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingPhase 3Tokyo Medical and Dental UniversityNCT06135714One endocrine option while metastasis-directed therapy is addedReport a problem
- An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyRecruitingPhase 2Fudan UniversityNCT07117630In every armBackbone while metabolic drugs or a PARP inhibitor are addedWritten as FulvestrantReport a problem
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingPhase 2MedSIRNCT07619066In every armPartner of zongertinib in HER2-mutant diseaseWritten as FulvestrantReport a problem
- Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.RecruitingPhase 2University of California, San DiegoNCT07227233Partner while a second CDK4/6 inhibitor is chosen by machine learningReport a problem
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395In every armEvery arm takes it with a gene-matched drugWritten as FulvestrantReport a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06941142In every armWith palbociclib while albumin-bound sirolimus is addedWritten as Fulvestrant injectionReport a problem
- Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibitorsNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06929325In every armBoth arms take it while albumin-bound sirolimus is addedWritten as Fulvestrant InjectionReport a problem
- Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06607757In every armBoth arms take it while capivasertib is added in lobular cancerWritten as Fulvestrant injectionReport a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNot applicableFudan UniversityNCT06856200In every armWith palbociclib while albumin-bound sirolimus is addedWritten as FulvestrantReport a problem
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03939897In every armUsual treatment with abemaciclib while copanlisib is addedWritten as FulvestrantReport a problem
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingPhase 3AstraZenecaNCT06764186In every armPartner of capivasertib, a phase 3b studyWritten as FulvestrantReport a problem
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedPhase 2UNICANCERNCT05625087Both arms take it; alpelisib against ribociclib on ctDNAReport a problem
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05169567In every armBoth arms take it while abemaciclib is added (postMONARCH)Written as FulvestrantReport a problem
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05038735In every armBoth arms take it while alpelisib is addedWritten as FulvestrantReport a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04544189In every armBoth arms take it while alpelisib is addedWritten as FulvestrantReport a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04524000In every armPartner of alpelisib in Japanese patientsWritten as FulvestrantReport a problem
Showing 20 of 54. See all 54 →
Beside a new treatment under test · 271 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Fulvestrant: dalpiciclib 14 · pyrotinib 11 · tucidinostat 8 · capivasertib 6 · culmerciclib 6 · Alpelisib 6 · abemaciclib 5 · inavolisib 5
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Optional endocrine partner beside new inavolisibReport a problem
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingPhase 1Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.NCT07923214Partner of new CG-7321 in some breast cancer cohortsWritten as FulvestrantReport a problem
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerRecruitingPhase 1Prelude Therapeutics IncorporatedNCT07905001Partner of new PRT13722Written as FulvestrantReport a problem
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 2PfizerNCT04557449Partner of new atirmociclib in some armsWritten as FulvestrantReport a problem
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsRecruitingPhase 1/2Qurient Co., Ltd.NCT05394103Partner of new mocaciclib in one cohortWritten as FulvestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Partner of new drugs in some platform armsWritten as FulvestrantReport a problem
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingPhase 1Genentech, Inc.NCT07867262Partner of new GDC-4198 in one armWritten as FulvestrantReport a problem
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruitingPhase 3Relay Therapeutics, Inc.NCT06982521In every armBoth arms take it; new zovegalisib against capivasertibWritten as FulvestrantReport a problem
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsRecruitingPhase 1IDEAYA BiosciencesNCT07540572Partner of new IDE574 in the combination cohortsWritten as Fulvestrant injectionReport a problem
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsRecruitingPhase 1NiKang Therapeutics, Inc.NCT07029399Partner of new NKT5097Written as FulvestrantReport a problem
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingPhase 1PfizerNCT07318805Partner of new PF-08032562 in one partWritten as FulvestrantReport a problem
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingPhase 1Eli Lilly and CompanyNCT07114601One standard partner of new LY4257496Report a problem
- Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruitingPhase 1Novartis PharmaceuticalsNCT07604571Partner of new IEV407Written as FulvestrantReport a problem
- Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruitingPhase 1/2Novartis PharmaceuticalsNCT07288359Partner of new GVV858Written as FulvestrantReport a problem
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1PfizerNCT07897721Partner of new PF-08165784Written as FulvestrantReport a problem
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsRecruitingPhase 1/2Terremoto Biosciences Inc.NCT07109726Partner of new TER-2013Written as Fulvestrant injectionReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862In every armBoth arms take it; new inavolisib against alpelisibWritten as FulvestrantReport a problem
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Partner of pyrotinib and dalpiciclib after trastuzumab rezetecanWritten as FulvestrantReport a problem
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06555068Partner of new HRS-6209Written as HRS-6209 in Combination with FulvestrantReport a problem
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Partner of new AMXT 1501Written as FulvestrantReport a problem
Showing 20 of 271. See all 271 →
Beside supportive care · 13 — a supportive treatment or test is studied
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303In every armTreatment whose response FFNP-PET imaging predictsWritten as FulvestrantReport a problem
- Rash & Diarrhea Prophylaxis With CapivasertibRecruitingPhase 2Maryam LustbergNCT07426822In every armTreatment while rash and diarrhoea prophylaxis is testedWritten as FulvestrantReport a problem
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05090358In every armTreatment while diets or canagliflozin prevent hyperglycaemiaWritten as FulvestrantReport a problem
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsCompletedPhase 2MedSIRNCT04300790In every armTreatment while metformin prevents alpelisib hyperglycaemiaWritten as FulvestrantReport a problem
- Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedPhase 2Novartis PharmaceuticalsNCT04899349In every armTreatment while dapagliflozin prevents hyperglycaemiaWritten as FulvestrantReport a problem
- Analysis of Circulating Tumor Markers in the Blood (ALCINA)CompletedNot applicableInstitut CurieNCT02866149Treatment during which blood markers are studiedReport a problem
- A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT05966584Treatment while benralizumab prevents alpelisib rashReport a problem
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedPhase 4Palleos Healthcare GmbHNCT03220178In every armTreatment while eHealth support is testedWritten as FulvestrantReport a problem
- PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast CancerTerminatedNot applicableBritish Columbia Cancer AgencyNCT00816582Treatment guided by PET/CTReport a problem
- FES-PET for Patients Treated on NCI Protocol 8762WithdrawnNot applicableWashington University School of MedicineNCT01714128Treatment during which FES-PET is studiedReport a problem
- Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast CancerStatus unknownPhase 2Saint Luke's Health SystemNCT05025735Treatment while dapagliflozin is added against hyperglycaemiaReport a problem
- Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast CancerCompletedNot applicableZhimin ShaoNCT03507088Treatment whose response FES-PET predictsReport a problem
- The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast CancerStatus unknownNot applicableFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT03768479Treatment whose efficacy FES-PET/CT predictsReport a problem
One option of several · 64 — a test or a strategy chooses among drugs
- Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBCNot yet recruitingPhase 2Harbin Medical UniversityNCT07935226In every armOne endocrine option with dalpiciclib in both armsReport a problem
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingPhase 1/2RayzeBio, Inc.NCT06590857One endocrine choice beside new RYZ101Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One matched combination in ComboMATCHWritten as FulvestrantReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336In every armOne endocrine option while new tersolisib is addedWritten as FulvestrantReport a problem
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingPhase 3American Society of Clinical OncologyNCT06377852One endocrine option while CDK4/6 dosing is studiedReport a problem
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04923542One endocrine option beside abemaciclib and radiosurgeryReport a problem
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269In every armOne partner in an alpelisib roll-overWritten as FulvestrantReport a problem
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingPhase 3SWOG Cancer Research NetworkNCT07802626One endocrine option while capivasertib is addedReport a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingPhase 2University of California, San DiegoNCT07729046One endocrine option while neratinib is addedReport a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786In every armOne endocrine option alone for older womenWritten as FulvestrantReport a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingPhase 2Oana DanciuNCT05467891In every armOne endocrine option with ribociclib for locoregional recurrenceWritten as FulvestrantReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One option in molecular-typed salivary treatmentWritten as alpelisib+fulvestrantReport a problem
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06409390In every armOne drug in an evolution-guided sequenceWritten as FulvestrantReport a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingPhase 3Region Örebro CountyNCT06044623One endocrine option, lower CDK4/6 starting dose in older patientsReport a problem
- T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationPhase 2Zheng YabingNCT06481956One endocrine option with ribociclib and T-DM1Report a problem
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingPhase 2Li HuipingNCT06339281One partner of apatinib by physician's choiceWritten as apatinib mesylate+Fulvestrant injectionReport a problem
- Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingPhase 2Fudan UniversityNCT05205200One endocrine option in an immunotherapy umbrella (ENIGMA)Written as SERDReport a problem
- Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast CancerRecruitingPhase 2Gangnam Severance HospitalNCT03750396One endocrine option while local treatment is addedReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingPhase 3Alliance Foundation Trials, LLC.NCT02947685In every armOne endocrine option while palbociclib is added (PATINA)Written as FulvestrantReport a problem
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingPhase 4Novartis PharmaceuticalsNCT05161195In every armOne endocrine partner in a ribociclib roll-overWritten as FulvestrantReport a problem
Showing 20 of 64. See all 64 →
Given beside what is tested · 1 — usual care or a partner of the new treatment
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingPhase 3LeonaBioNCT05696626Comparator with abemaciclib against new lasofoxifene (ELAINE-3)Written as Fulvestrant in combination with abemaciclibReport a problem
As the comparator · 29 — what is tested is compared with Fulvestrant
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751One endocrine option in the comparator against new saruparibWritten as FulvestrantReport a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Partner of new gedatolisib; comparator with ribociclib (VIKTORIA-2)Written as Arm A: Gedatolisib + Palbociclib + FulvestrantReport a problem
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596One comparator option for new opevesostat in breast cancerWritten as FulvestrantReport a problem
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173One comparator option for new HRS-8080Written as Fulvestrant injectionReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883One endocrine option in the comparator against T-DXdReport a problem
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07354022Comparator with dalpiciclib for new HRS-8080Written as Fulvestrant injection ;Dalpiciclib IsethionateReport a problem
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792One endocrine option against partial breast irradiationWritten as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifeneReport a problem
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerRecruitingPhase 3InventisBio Co., LtdNCT06954961Comparator for new taragarestrantWritten as FulvestrantReport a problem
- A Study of Single Dose of BL0175 in Postmenopausal WomenNot yet recruitingPhase 1Shanghai Best-Link Bioscience, LLCNCT07366632Reference for new BL0175, single dosesWritten as FulvestrantReport a problem
- Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingPhase 2National University Hospital, SingaporeNCT05181033Comparator for lenvatinib with letrozoleWritten as FulvestrantReport a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingPhase 2Yonsei UniversityNCT06837792One comparator option against T-DXdReport a problem
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingPhase 2Henan Cancer HospitalNCT06176534One endocrine option in the comparator against chemotherapyReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340One comparator option for new giredestrant (evERA)Written as FulvestrantReport a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Comparator for new giredestrant (pionERA)Written as FulvestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingPhase 2Hoffmann-La RocheNCT04576455One comparator option for new giredestrant (acelERA)Report a problem
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingPhase 2AstraZenecaNCT04214288Comparator for new camizestrant (SERENA-2)Written as FulvestrantReport a problem
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingPhase 3Olema Pharmaceuticals, Inc.NCT06016738One comparator option for new palazestrant (OPERA-01)Written as FulvestrantReport a problem
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921One comparator option for new SIM0270Written as Fulvestrant injectionReport a problem
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT04975308Comparator option for new imlunestrant (EMBER-3)Written as FulvestrantReport a problem
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingPhase 3PfizerNCT05654623Comparator for new vepdegestrant (VERITAC-2)Written as FulvestrantReport a problem
Showing 20 of 29. See all 29 →
Observed · 53 — patients on it are followed, or it is given outside a trial
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingHoffmann-La RocheNCT07347600Beside inavolisib, observedWritten as FulvestrantReport a problem
- Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .RecruitingHunan Cancer HospitalNCT06734533One partner of anlotinib in practiceReport a problem
- Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast CancerRecruitingSciClone PharmaceuticalsNCT06548919Among endocrine treatments for ESR1-mutated disease in ChinaReport a problem
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast CancerNot yet recruitingThe Affiliated Hospital of Qingdao UniversityNCT06341283One endocrine partner of abemaciclib in practiceWritten as FulvestrantReport a problem
- Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer PatientsRecruitingPeking Union Medical College HospitalNCT05680194One option in an elderly breast cancer cohortReport a problem
- Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantCompletedAstraZenecaNCT07008963Interviews with patients who took it with capivasertibReport a problem
- Swedish Ibrance Registries Insights (SIRI)CompletedPfizerNCT04654208One endocrine partner of palbociclib in Swedish practiceReport a problem
- A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNovartis PharmaceuticalsNCT04943497One partner of ribociclib or alpelisib in practiceReport a problem
- A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketCompletedPfizerNCT07096024With palbociclib after marketing in JapanWritten as palbociclib plus fulvestrantReport a problem
- Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf RegionCompletedPfizerNCT04916509One endocrine partner of palbociclib in practiceWritten as Palbociclib plus fulvestrantReport a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingPfizerNCT04767594One endocrine partner of palbociclib, first-lineReport a problem
- TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.CompletedPfizerNCT04498481One endocrine partner of palbociclib in community practiceReport a problem
- Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNovartis PharmaceuticalsNCT05022342With alpelisib in practiceReport a problem
- A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNovartis PharmaceuticalsNCT06311383One endocrine partner of ribociclib in practiceReport a problem
- A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNovartis PharmaceuticalsNCT04967248With alpelisib in practiceReport a problem
- Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer PatientsCompletedTechnical University of MunichNCT04681768One endocrine partner of abemaciclib in practiceReport a problem
- Young Patients With Early Breast CancerActive, not recruitingPeking Union Medical College HospitalNCT06027541One option in a young breast cancer cohortReport a problem
- Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)CompletedMedSIRNCT06525675Long-term survival from PARSIFALWritten as Fulvestrant Injectable ProductReport a problem
- 500mg Fulvestrant in HR+ MBCCompletedFudan UniversityNCT03708432The 500 mg dose in practiceReport a problem
- Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.CompletedPfizerNCT04460911With palbociclib in US community practiceReport a problem
Showing 20 of 53. See all 53 →
As a tool · 2 — an imaging tracer or a test of drug response
- Impact of Endogenous E2 on SSI and GH ReboundCompletedPhase 1Mayo ClinicNCT02026973A tool to block oestrogen in a growth-hormone studyWritten as FulvestrantReport a problem
- Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal WomenCompletedPhase 1Mayo ClinicNCT01186796A tool to block oestrogen in a growth-hormone studyWritten as FulvestrantReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNov 16, 2026NCT07937605
Codes
What other systems call Fulvestrant · ClinicalTrials.gg INT006680
- MeSH (NLM) D000077267FulvestrantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 22X328QOC4FULVESTRANTConfirmed FDA, NLM, Wikidata
- RxNorm 282357Confirmed FDA, Wikidata
- Wikidata Q5508491fulvestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1379FulvestrantOne source FDA
- DrugBank DB00947One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077267 | Fulvestrant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 22X328QOC4 | FULVESTRANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 282357 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5508491 | fulvestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1379 | Fulvestrant | One source FDA |
| DrugBank | DB00947 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.